9 results on '"Livi, Lorenzo"'
Search Results
2. Leiomyosarcoma: Clinicopathological study and retrospective analysis of prognostic factors in a series of 100 patients.
- Author
-
Muratori, Francesco, Greto, Daniela, Cenatiempo, Mauro, Mazzei, Giacomo, Frenos, Filippo, Roselli, Giuliana, Livi, Lorenzo, Capanna, Rodolfo, Baldi, Giacomo, and Campanacci, Domenico Andrea
- Subjects
AGE factors in disease ,CANCER relapse ,METASTASIS ,SURVIVAL ,TUMORS ,RETROSPECTIVE studies ,LEIOMYOSARCOMA ,TUMOR grading - Abstract
The Authors reported a retrospective study of 100 Leiomyosarcoma (LMS), evaluating factors that may influence Overall Survival (OS), Local Recurrence Free Survival (LRFS), Metastasis Free Survival (MFS). Tumor Size (P=0,0009), Local Recurrence (P=0,0487), Distant relapse (P < 0,0001), Type of Presentation (P=0,0213) were significant risk factors affecting overall survival (OS). Tumor Size (P=0.024), age at diagnosis (P=0,0086), type of presentation (P < 0,0001) and Local Recurrence (P=0.0152) affected metastasis free survival (MFS). Type of presentation (P=0,001) was an independent prognostic factor of local recurrence-free survival (LRFS). [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
3. Selection criteria for stereotactic body radiation treatment of spinal metastases.
- Author
-
Aquilano, Michele, Loi, Mauro, Lucidi, Sara, Francolini, Giulio, Simontacchi, Gabriele, Greto, Daniela, Desideri, Isacco, Bonomo, Pierluigi, Allegra, Andrea Gaetano, Angelini, Lucia, Masi, Laura, Doro, Raffaella, Bonucci, Ivano, Di cataldo, Vanessa, Mangoni, Monica, and Livi, Lorenzo
- Subjects
PROGRESSION-free survival ,STEREOTACTIC radiotherapy ,METASTASIS ,PATIENT selection ,SYMPTOMS - Abstract
Purpose or objective: Stereotactic Body Radiotherapy (SBRT) is widely used for treatment of uncomplicated spine metastases to palliate symptoms and prolong disease control. However, criteria for patient selection are not available. The aim of this study is to identify determinants of local failure and progression-free interval in patients treated with SBRT to spinal metastases. Materials and methods: Data from consecutive patients treated with Cyberknife-based spine SBRT between January 2019 and March 2020 were retrospectively collected. Dose was expressed as Biological Effective Dose for α/β=10 (BED10). Kaplan-Meyer method was used to calculate Local Control (LC) and Disease Free Survival (DFS) from date of SBRT to event. Univariate (UVA) and Multivariate analysis (MVA) were performed using log-rank and Cox model, respectively. Results: Sixty-two patients accounting for 70 spinal metastases were included. Median age was 66 (range 32- 87) years. Disease was metastatic at diagnosis in 21 patients (34%) : an active primary tumor was present in 17 patients (27%). Among treated sites, most represented primary malignancies were prostate (n=28, 40%) and breast (n=21, 30%). Dose regimens consisted of 25-30 Gy in 5 fractions and 21-30 Gy in 3 fractions in respectively 61 (87%) and 9 (13%) cases, resulting in a median BED of 43.2 (range 37.5-60) Gy10. Concurrent chemotherapy (including cytotoxic or targeted agents) was administered in 43% of cases (n=30). After a median follow up of 10 months (range 1-24 months), 9 local relapses and 40 distant progressions were observed. One year LC was 87% (Fig.1): nonprostate primary tumor (p=0.003, Fig.2) and concurrent chemotherapy (p=0.006, Fig.3) were associated to poorer LC at UVA, and an independent correlation was confirmed at MVA (respectively p=0.017 and p=0.024). One-year DFS was 43% (Fig.4). UVA showed a correlation between impaired DFS and active primary tumor (p=0.003), metastatic dissemination at diagnosis (p=0.02) and nonprostate primary tumor (p=0.009), although only an active primary tumor site was independently associated to DFS at MVA (p=0.007, Fig.5). Only G2 acute pain or nausea were observed. No late toxicity, in particular vertebral fracture, was reported. Conclusion: Spine SBRT results in high LC rates and durable progression-free survival with low incidence of mild toxicity. Clinical nomograms based on patient-related characteristics may help to select candidates for this approach. [ABSTRACT FROM AUTHOR]
- Published
- 2022
4. Judging a Fish by Its Ability to Climb a Tree? A Call for Novel Endpoints in the Appraisal of Ablative Local Treatments of Oligometastatic Cancer.
- Author
-
Loi, Mauro, Alifano, Marco, Scorsetti, Marta, Nuyttens, Joost J., and Livi, Lorenzo
- Subjects
TUMOR surgery ,BIOMARKERS ,DISEASE progression ,METASTASIS ,CANCER patients ,RADIOSURGERY ,ABLATION techniques - Abstract
This commentary addresses the need for novel endpoints in clinical research to assess the added value of local treatment of metastases in oligometastatic patients and in patients experiencing limited metastatic progression during systemic therapy (oligoprogressive). Novel metrics are proposed for future implementation in clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Could stereotactic body radiotherapy be a valid option in metastatic lung cancer with oligoprogressive disease?
- Author
-
Aquilano, Michele, Loi, Mauro, Livi, Lorenzo, and Nuyttens, Joost
- Subjects
STEREOTACTIC radiotherapy ,LUNG cancer ,METASTASIS ,PROGNOSIS ,OVERALL survival - Abstract
Purpose or objective: Oligoprogression (OPD) is defined as a condition where limited progression (1-3 metastases) is observed in patients undergoing systemic cancer treatment. Local treatment of OPD might delay systemic therapy line switch, which could be beneficial in patients experiencing prolonged global disease control with novel targeted or immune therapies. In this study we investigated the impact on outcome of stereotactic body radiotherapy (SBRT) in patients with OPD from metastatic lung cancer. Materials and methods: Data from a cohort of consecutive patients treated with Cyberknife and Linacbased SBRT between June 2015 and August 2021 were collected. All extracranial metastatic sites of OPD from lung cancer were included. Dose regimens consisted of 24 in 2 fractions, 30-51 Gy in 3 fractions, 30-55 Gy in 5 fractions, 52.5 Gy in 7 fractions and 44-56 Gy in 8 fractions. Dose was expressed as Biological Effective Dose for α/β=10 (BED10). Kaplan-Meyer method was used to calculate Overall Survival (OS), Local Control (LC) and Disease Progression-free Survival (DPFS) from the start date of SBRT to event. Results: Sixty-three patients, 34 female and 29 male were included. Median age was 75 years (range 25–83). All patients received concurrent systemic treatment before the start of the SBRT: 19 chemotherapy (CT) alone (30%), 26 CT plus immunotherapy (IT) or plus Tyrosin kinase inhibitors (TKI) (41%) and 18 IT/TKI alone (29%). SBRT was delivered to lung (n=29), mediastinal node (n=9), bone (n=7), adrenal gland (n=19), other visceral metastases (1) and other node metastases (n=4). A median BED10 of 104 (range 39-151) Gy10 was delivered. After a median follow up of 20 months (range 1-48), median overall survival was median OS was 23 months (figure 1). LC was 93% at 1 year and 87% at 2 years. DPFS was 7 months. At univariate analysis, age, type of systemic treatment, metastatic site receiving SBRT and BED were not significant prognostic factors for overall survival. Conclusion: SBRT in lung cancer patients for oligoprogression resulted in a long median OS of 23 months. One-year LC was 93%. Median DPFS was 7 months, translating into continuation of effective systemic treatment as other metastases grow slowly. SBRT could be useful to postpone the change of chemotherapy and/or immunotherapy. More research is needed to select OPD patients eligible for SBRT. [ABSTRACT FROM AUTHOR]
- Published
- 2022
6. Predicting the status of axillary lymph nodes in breast cancer: A multiparameter approach including axillary ultrasound scanning.
- Author
-
Susini, Tommaso, Nori, Jacopo, Olivieri, Simone, Molino, Cecilia, Marini, Giulia, Bianchi, Simonetta, Vezzosi, Vania, Livi, Lorenzo, Mascalchi, Mario, and Scarselli, Gianfranco
- Subjects
LYMPH node cancer ,MEDICAL imaging systems ,CANCER patients ,METASTASIS ,LONGITUDINAL method ,ONCOLOGIC surgery ,BREAST cancer ,MEDICAL ultrasonics - Abstract
Abstract: In a prospective study, we attempted to predict axillary metastases in 135 breast cancer patients by a preoperative multiparameter evaluation including axillary ultrasound scanning (US). After surgery, factors associated with lymph node metastases by univariate analysis were included in a multivariate model. By multivariate analysis, the stronger independent predictors of lymph node metastases were suspicious axillary US (p <0.001), tumor location in the outer quadrants (p =0.001) and high Ki-67 index (>10%) (p =0.002). A predictive model based on these variables, identified a high-risk group (20.0%) represented by women with suspicious axillary US, tumor in the outer quadrants and high Ki-67 index, with axillary metastases in 100%, whereas all patients with opposite features (8.1%) had uninvolved axillary lymph nodes. This multiparameter evaluation including axillary US may be used to optimize the selection of breast cancer patients candidate to sentinel lymph node biopsy or axillary lymph node dissection. The accuracy of this predictive model still requires prospective validation in a larger sample of women. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
7. Liposarcoma: Clinico-pathological analysis, prognostic factors and survival in a series of 307 patients treated at a single institution.
- Author
-
Muratori, Francesco, Frenos, Filippo, Bettini, Leonardo, Matera, Davide, Mondanelli, Nicola, Scorianz, Maurizio, Cuomo, Pierluigi, Scoccianti, Guido, Beltrami, Giovanni, Greto, Daniela, Livi, Lorenzo, Baldi, Giacomo, Roselli, Giuliana, Capanna, Rodolfo, and Campanacci, Domenico Andrea
- Subjects
- *
LIPOSARCOMA , *MULTIVARIATE analysis , *METASTASIS , *RADIOTHERAPY , *CANCER chemotherapy , *CANCER relapse , *PROGNOSIS , *SOFT tissue tumors , *SURVIVAL , *RETROSPECTIVE studies , *TUMOR grading , *THERAPEUTICS , *TUMOR treatment - Abstract
Background and Objectives: Liposarcoma (LPS) is a malignant mesenchymal tumor and the most common soft tissue sarcoma. Four different subtypes are described: well differentiated (WD) LPS or atypical lipomatous tumor (ALT), dedifferentiated (DD) LPS, myxoid LPS, and pleomorphic LPS (PLS). The objective of the study was to investigate prognostic factors and clinical outcome of liposarcoma.Methods: We retrospectively examined the clinico-pathological features of a series of 307 patients affected by Liposarcoma at a mean follow-up of 69 months (range 6-257). ALT/WD LPS were analyzed separately. The influence of site, size, type of presentation, grading, histotype and local recurrence on local and systemic control and survival was assessed.Results: The statistical analysis indicated that only surgical margins represented a significant prognostic factor for local recurrence in ALT/WD LPS (P = 0.0007) and other subtypes of LPS (P = 0.0055). In myxoid, PLS and DD LPS, significant prognostic factors for metastasis free survival (MFS) were surgical margins (P = 0.0009), size of the tumor (P = 0.0358), histology (P = 0.0117) and local recurrence (P = 0.0015). In multivariate analysis, surgical margins (0.0180), size (0.0432) and local recurrence (0.0288) correlated independently with MFS. Margins (P = 0.0315), local recurrence (P = 0.0482) and metastases (P < 0.0001) were prognostic factors for overall survival (OS).Conclusion: Marginal surgery can be an accepted treatment for ALT/WD LPS. In other liposarcoma subtypes (Myxoid, DD, PLS) wide or radical surgery is recommended as the margins significantly influence local recurrence-free survival (LRFS), metastasis-free survival (MFS) and overall survival (OS). Local recurrence and metastases were significant prognostic factors for OS. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
8. Myxoid Liposarcoma: Prognostic Factors and Metastatic Pattern in a Series of 148 Patients Treated at a Single Institution.
- Author
-
Muratori, Francesco, Bettini, Leonardo, Frenos, Filippo, Mondanelli, Nicola, Greto, Daniela, Livi, Lorenzo, Franchi, Alessandro, Roselli, Giuliana, Scorianz, Maurizio, Capanna, Rodolfo, and Campanacci, Domenico
- Subjects
- *
LIPOSARCOMA , *ADIPOSE tissue cancer , *METASTASIS , *CANCER patients , *HEALTH outcome assessment - Abstract
Objectives. The authors reported a retrospective study on myxoid liposarcomas (MLs), evaluating factors that may influence overall survival (OS), local recurrence-free survival (LRFS), metastasis-free survival (MFS), and analyzing the metastatic pattern.Methods. 148 MLs were analyzed. The sites of metastases were investigated.Results. Margins (p = 0.002), grading (p = 0,0479), and metastasis (p < 0,0001) were significant risk factors affecting overall survival (OS). Type of presentation (p = 0.0243), grading (p = 0,0055), margin (p = 0.0001), and local recurrence (0.0437) were risk factors on metastasis-free survival (MFS). Authors did not observe statistically significant risk factors for local recurrence-free survival (LRFS) and reported 55% extrapulmonary metastases and 45% pulmonary metastases.Conclusion. Margins, grading, presentation, local recurrence, and metastasis were prognostic factors. Extrapulmonary metastases were more frequent in myxoid liposarcoma. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
9. Stereotactic body radiotherapy (SBRT) in combination with drugs in metastatic kidney cancer: A systematic review.
- Author
-
Ingrosso, Gianluca, Becherini, Carlotta, Francolini, Giulio, Lancia, Andrea, Alì, Emanuele, Caini, Saverio, Teriaca, Maria Ausilia, Marchionni, Alessandro, Filippi, Andrea Riccardo, Livi, Lorenzo, Sanguineti, Giuseppe, Aristei, Cynthia, and Detti, Beatrice
- Subjects
- *
STEREOTACTIC radiotherapy , *RENAL cancer , *METASTASIS , *TREATMENT effectiveness , *KINASES - Abstract
• Tyrosine Kinases Inhibitors were used in combination with SBRT in 93% of cases. • Radiotherapy schedules of single fraction doses were 10–20 Gy. • Radiotherapy schedules of hypofractionated doses were 35–60 Gy in 3–5 fractions. • Local control of irradiated lesions was achieved in 76–100% of the patients. • The 2-year overall survival was 71% after combined approach. To conduct a systematic review and meta-analysis of the role of SBRTdrug combination in patients affected by mRCC and associated oncologic outcomes and toxicity profiles. We performed a critical review of the Pubmed, Medline, and Embase databases from January 1, 2000 through April 30, 2020 according to the Preferred Reporting Items and Meta-Analyses statement. To assess the overall quality of the literature reviewed, we used a modified Delphi tool. A total of 6 studies were included, corresponding to a cohort of 216 patients. Tyrosine Kinases Inhibitors were the most widely used drugs in combination with SBRT, being administered in 93% patients. No study reported an increase of radiation-induced toxicity. SBRT resulted to be safe, without increase in terms of drugs-related adverse events in this setting. Moreover, this approach showed promising clinical outcomes in terms of LC and OS [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.